b.) Amendments to the Claims

1. (Currently Amended) A piperidine derivative represented by formula (I):



(I)

wherein

m represents an integer of 0 to 5;

R^1 and R^2 independently represent a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group, a substituted or unsubstituted lower alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heterocyclic group;

R^3 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group; and

X represents a bond or CO;

or a pharmaceutically acceptable salt thereof,

wherein the heterocyclic groups in R^1, R^2 and R^3 independently represent (i) a 5- or 6-membered monocyclic aromatic heterocyclic group containing ~~at least one nitrogen, oxygen or sulfur atom~~ 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, (ii) an aromatic heterocyclic group having two or three fused 3- to 8-membered rings and containing ~~at~~

~~least one nitrogen, oxygen or sulfur atom~~ 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom ~~having two or three fused 3- to 8-membered rings~~, (iii) a 5- or 6-membered monocyclic alicyclic heterocyclic group containing ~~at least one nitrogen, oxygen or sulfur atom~~ 1 or 2 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or (iv) an alicyclic heterocyclic group having two or three fused 3- to 8-membered rings and containing ~~at least nitrogen, oxygen or a sulfur atom~~ 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom ~~having two or three fused 3- to 8-membered rings~~,

wherein at least one of R^1, R^2, and R^3 is 6-membered monocyclic aromatic heterocylic group or a 6-membered monocyclic alicyclic heterocyclic group.

2. (Original) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein R^1 is a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heterocyclic group, and R^2 is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group.

3. (Original) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 1 and X is a bond.

4. (Original) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 2, wherein m is 1 and X is a bond.

5. (Original) A pharmaceutical composition which comprises as an active ingredient the piperidine derivative or the pharmaceutically acceptable salt thereof

according to any one of claims 1 to 4, and a pharmaceutically acceptable diluent or carrier.

6. (Previously Presented) A method of treating a patient with cancer, which comprises administrating to said patient a pharmacologically effective amount of the piperidine derivative or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.

7. (Previously Presented) The method of treating a patient according to claim 9, wherein the tumor is pancreatic cancer.

8. (Previously Presented) The method of treating a patient according to claim 9, wherein the tumor is colon cancer.

9. (Previously Presented) The method of treating a patient according to claim 6, wherein the cancer is a tumor.

10. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 0.

11. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 1.

12. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 2.

13. (Previously Presented) The piperidine derivative or the

pharmaceutically acceptable salt thereof according to claim 1, wherein m is 3.

14. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 4.

15. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 1, wherein m is 5.

16. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 10, wherein X is a bond.

17. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 12, wherein X is a bond.

18. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 13, wherein X is a bond.

19. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 14, wherein X is a bond.

20. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 15, wherein X is a bond.

21. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 10, wherein X is CO.

22. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 11, wherein X is CO.

23. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 12, wherein X is CO.

24. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 13, wherein X is CO.

25. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 14, wherein X is CO.

26. (Previously Presented) The piperidine derivative or the pharmaceutically acceptable salt thereof according to claim 15 wherein X is CO.